Health Economics of Peptide Therapeutics: Cost-Effectiveness and Market Access

Overview

Health economics evaluates the value and affordability of peptide therapeutics. Understanding cost-effectiveness, pricing strategies, and market access is crucial for ensuring patient access to innovative peptide drugs.

Key Concepts

Cost-Effectiveness Analysis

Pharmacoeconomic Models

• Cost-effectiveness analysis (CEA): Cost per quality-adjusted life year (QALY)
• Cost-utility analysis (CUA): Patient-reported outcomes
• Cost-benefit analysis (CBA): Monetary value of health benefits
• Cost-minimization analysis (CMA): Equivalent outcomes, lowest cost

Budget Impact Analysis

• Annual budget impact: Total cost to healthcare system
• Patient population: Prevalence and incidence
• Market share projections: Expected uptake
• Indirect costs: Productivity, caregiver burden

Pricing Strategies

Value-Based Pricing

• Clinical value: Efficacy and safety benefits
• Innovation value: Novel mechanism of action
• Comparative effectiveness: vs. standard of care
• Willingness to pay: Threshold analysis (e.g., $50,000-150,000/QALY)

Cost-Plus Pricing

• Manufacturing costs: Raw materials, production
• Development costs: R&D amortization
• Distribution costs: Cold chain, logistics
• Profit margin: Reasonable return on investment

Outcomes-Based Contracts

• Performance guarantees: Refund if targets not met
• Risk-sharing agreements: Payer and manufacturer
• Real-world evidence: Post-launch outcomes monitoring
• Payment by results: Tied to clinical outcomes

Market Access Pathways

Payer Coverage Decisions

• Health technology assessment (HTA): NICE, PBAC, CADTH
• Coverage with evidence development: Conditional reimbursement
• Managed entry agreements: Confidential discounts
• Patient access schemes: Copay assistance, free drug programs

Formulary Placement

• Preferred tier: Lowest patient cost
• Non-preferred tier: Higher cost-sharing
• Prior authorization: Required for coverage
• Step therapy: Try alternatives first

Patient Assistance Programs

• Manufacturer copay cards: Reduced patient out-of-pocket
• Foundation support: Independent charitable aid
• State pharmaceutical assistance: Government programs
• International reference pricing: Global price comparison

Biosimilar Economics

Market Impact

• Price competition: 30-50% cost reduction
• Market share erosion: Reference product decline
• Total cost of ownership: Including administration costs
• Patient access: Increased availability

Switching and Interchangeability

• Non-medical switching: Cost-driven transitions
• Pharmacy substitution: Automatic dispensing
• Physician preference: Clinical familiarity
• Patient education: Biosimilar acceptance

Rare Disease Economics

Orphan Drug Economics

• Small patient populations: High per-patient cost
• Limited competition: Market exclusivity
• Specialized centers: Concentrated expertise
• Patient registries: Natural history data

Gene Therapy Pricing

• One-time treatment: Curative potential
• High upfront cost: >$1 million
• Long-term value: Lifetime cost offset
• Annuity models: Payment over time

Real-World Evidence

Post-Launch Monitoring

• Effectiveness studies: Real-world efficacy
• Safety surveillance: Pharmacovigilance
• Utilization patterns: Prescribing behavior
• Patient outcomes: Quality of life assessment

Data Sources

• Electronic health records: Clinical outcomes
• Claims data: Utilization and costs
• Patient registries: Disease-specific data
• Wearable devices: Continuous monitoring

Economic Models

Markov Models

• Health states: Disease progression stages
• Transition probabilities: State changes over time
• Costs and utilities: Per-state values
• Time horizon: Lifetime analysis

Decision Tree Models

• Clinical pathways: Treatment sequences
• Probability nodes: Event occurrence
• Cost nodes: Resource utilization
• Sensitivity analysis: Parameter uncertainty

Microsimulation Models

• Individual-level simulation: Patient trajectories
• Heterogeneity: Patient-specific characteristics
• Complex interactions: Multiple disease processes
• Calibration: Real-world data fitting

Policy Implications

Value Frameworks

• ASCO Value Framework: Cancer treatment value
• NICE criteria: UK HTA threshold
• ICER value assessment: US comparative effectiveness
• G-BA assessment: German benefit evaluation

Coverage Policies

• Essential health benefits: ACA requirements
• Medicare coverage: Part B and Part D
• Medicaid formularies: State-level decisions
• Veterans Affairs: Federal procurement

Global Access

• Tiered pricing: Income-based pricing
• Voluntary licensing: Manufacturing in developing countries
• Technology transfer: Local production capacity
• Global funds: PEPFAR, Gavi, Global Fund

References

• Lauenroth, A., et al. (2024). “Health economics of peptide therapeutics: a systematic review.” Value in Health, 27(3), 312-328.
• Garrison, L.P., et al. (2023). “Value-based pricing for biologics.” PharmacoEconomics, 41(8), 853-867.